7.30 am Check-In & Coffee + Light Breakfast
8:25 am Chair’s Opening Remarks
RECENT ADVANCEMENTS & EMERGING THERAPIES TO IMPROVE TREATMENT OPTIONS FOR WET AMD & DIABETIC EYE DISEASE
8:30 am Prolonging Drug Efficacy in Wet AMD: Innovations in Formulation & Delivery
Synopsis
- Examine the role of ocular pharmacogenetics in extending the duration of drug efficacy, focusing on how genetic variations can influence drug metabolism and response in the eye
- Explore advanced delivery systems which allow for higher drug concentrations and targeted delivery to enhance treatment longevity
- Discuss the use of polymers in drug formulations to create sustained-release mechanisms, improving the half-life and bioavailability of ocular drugs by ensuring a gradual and controlled release of the active ingredients
9:00 am An Overview on Pathways & Outcomes of Wet AMD & Diabetic Retinopathy
Synopsis
- Exploring molecular pathways contributing to diabetic retinopathy and wet AMD to understand variations in treatment efficacy
- Identifying key biomarkers that guide the selection of effective therapies and support combination approaches
- Addressing unmet needs by informing drug development with insights on patients who are unresponsive to current treatments
9:30 am ONS-5010: The First On-Label Bevacizumab Treatment for Wet AMD
Synopsis
- Addressing regulatory challenges to meet FDA approval
- Leveraging EMA support to establish ONS-5010 as a global standard for wet AMD treatment
- Explaining the product details, offering an affordable and effective alternative to compete in the crowded anti-VEGF market and reshape retinal care paradigms
10.00 am Speed Networking
Synopsis
An optimal chance to network one-to-one with leading retinal vascular experts working across early discovery, preclinical and clinical stages. Learn how your peers are developing better anti-VEGF drugs, new targets, new modalities and clinical
biomarkers and endpoints for better patient treatment and early disease detection.
10.30 am Morning Break & Refreshments
ANTI-VEGF COMBINATIONS & BEYOND: COMBATING RESISTANCE TO IMPROVE STANDARD OF CARE
11:00 am Addressing Treatment Resistance & Improving Outcomes in Retinal Vein Occlusion with a Novel Multimodal Eye Drop Therapy
Synopsis
- Overview of the E147 eye drop, a second-generation product targeting retinal vein occlusions with a unique mechanism of action
- Highlight the positive results from the pilot study and plans for upcoming US trials in retinal vein occlusion and diabetic retinopathy
- Discuss how the E147 eye drop’s ability to target multiple growth factors involved in vascular and fibrotic processes could help address the issue of treatment resistance and fibrosis associated with current anti-VEGF therapies
11:30 am RO-104, A First/Best-In-Class Trispecific Monotherapy with the Potential to Offer Superior & Sustained Vision for Wet AMD & DME Patients
Synopsis
- Leveraging the RevMod platform with fully human phage display library to identify novel CDRs instrumental in treating diseases of significant unmet need in ophthalmology and oncology
- Looking at the lead ophthalmology asset from RevMod platform, a fully human trispecific antibody (RO-104) targeting 3 clinically validated pathways in AMD and DME as monotherapy, potentially offering superior and sustained vision over standard of care
- Demonstrating early efficacy, safety, and tolerability of RO-104 across multiple animal (rat and NHP) models with a robust FIH study planned to start in Q4 2025 and designed to enable accelerated development path to pivotal trials and registration
12:00 pm Panel Discussion: How Can We Practically Implement New Treatments for Retinal Vascular Disorders, Streamlining Clinical Trials to Set Yourself Up for Success?
Synopsis
- How can you streamline trial design, incorporating new drug and technology advancements, to ensure a smoother transition through clinical phases for retinal therapies?
- What are the best strategies for forming partnerships and collaborations to support clinical development and commercialization efforts?
- How can patient engagement and feedback be integrated into the development process to enhance the efficacy and acceptance of new retinal therapies?
12.45 pm Lunch & Networking with Scientific Poster Session
Synopsis
This is an informal session to help you connect with your peers in a relaxed atmosphere to continue forging new and beneficial relationships. With an audience of translational, clinical, and commercial experts eager to hear the latest advancements in wet AMD & diabetic eye disease therapeutic development, you will have the opportunity to display a poster presenting your own work and innovations.
TRANSLATIONAL INNOVATIONS, PROACTIVE NPDR MANAGEMENT, & SUSTAINED-RELEASE SOLUTIONS TO PREVENT VISION LOSS & ENHANCE PATIENT CARE
2:00 pm Overcoming Translational Challenges in DR & DME: Holistic Approaches for Better Models
Synopsis
- Develop appropriate in vivo models that accurately replicate human disease conditions for diabetic retinopathy (DR) and diabetic macular edema (DME), addressing the limitations and variability of current rodent models
- Integrate computational and in vitro methods alongside in vivo studies to create a comprehensive, holistic approach for predicting drug efficacy and improving the translational success of preclinical findings
- Enhance collaboration between basic scientists and clinicians to refine these models, ensuring they capture the complex phenotypes of DR and DME, ultimately facilitating smoother transitions to clinical trials
2:30 pm Activating Soluble Guanylate Cyclase for Non-Proliferative Diabetic Retinopathy (NPDR) Treatment
Synopsis
- Presenting preclinical data on runcaciguat’s ability to activate soluble guanylate cyclase, aiming to improve retinal blood flow and reduce inflammation in NPDR
- Designing the Phase 2 NEON-NPDR trial to demonstrate how runcaciguat’s preclinical efficacy translates into clinical benefits for patients with NPDR
- Reflecting on current trial results that indicate potential improvements in retinal health and a reduced risk of vision-threatening complications
3:00 pm Sustained-Release Innovation for Wet AMD & DR with an Intravitreal Implant
Synopsis
- Discuss the limitations of current treatments for retinal diseases like wet AMD and Diabetic Retinopathy, which require frequent intravitreal injections, leading to increased risk of complications and patient discomfort
- Explore the advantages of AXPAXLI (OTX-TKI), a bioresorbable hydrogel implant designed to provide sustained release of axitinib, offering a broad antiangiogenic effect with the potential to extend treatment intervals to 6 months or longer
- Highlight the innovative product design, including the small fiber format, which aims to minimize visual impact and eliminate the need for preservatives, potentially improving patient outcomes and adherence
3.30 pm Afternoon Break & Refreshments
ADVANCING EARLY INTERVENTION & HOME MONITORING TECHNOLOGIES FOR IMPROVED PATIENT OUTCOMES
4:00 pm Fireside Chat: Early Intervention vs. Monitoring in NPDR: Navigating the Controversy
Synopsis
- Debate the merits of early treatment versus monitoring in non-proliferative diabetic retinopathy (NPDR), considering the potential to alter disease progression and prevent vision-threatening events
- Examine the significant industry investment in early intervention strategies, such as Genentech’s port delivery systems, and their potential to reduce the incidence of diabetic macular edema (DME) and other complications
- Analyze real-world data and expert opinions, noting that while historically most experts suggest a wait-and-see approach, the growing market and advancements in anti-VEGF therapies suggest a shift towards proactive treatment
4:45 pm Revolutionizing Wet AMD Care with Home Monitoring for Enhanced Patient Outcomes
Synopsis
- Expanding access to intravitreal injections and progressing towards at-home drug delivery methods to increase treatment accessibility and convenience for patients
- Implementing at-home OCT technologies and AI-driven telemonitoring systems for real-time monitoring of Wet AMD, significantly reducing the need for frequent clinic visits while maintaining stable visual acuity
- Reducing patient burden through personalized treatment algorithms that tailor regimens based on individual disease patterns, treatment responses, and medication durability, ultimately improving compliance and quality of life